CD5 KO CART19

CD5 KO CART19 is an experimental chimeric antigen receptor (CAR) T-cell therapy targeting CD19, modified using CRISPR-Cas9 to delete the CD5 gene. CD5 is a cysteine-rich scavenger receptor and negative regulator of T-cell activation; its genetic deletion is intended to enhance the anti-tumor activity, proliferation, and persistence of the CAR-T cells by removing inhibitory signaling. In preclinical models of B-cell acute lymphoblastic leukemia (B-ALL), CD5 KO CART19 demonstrated significantly enhanced leukemia control and peripheral blood expansion compared to wild-type CART19. The modification also appears to reduce T-cell exhaustion (lowering markers like PD-1 and LAG3) and increase the proportion of central memory T cells. This approach was developed by researchers at the University of Pennsylvania to improve the efficacy of CAR-T therapies in hematological malignancies.

Other names

CD5-knockout anti-CD19 CAR-T cellsCD-5-knockout anti-CD19 CAR-T cellsCD 5-knockout anti-CD19 CAR-T cellsCD5 KO CD19-directed CAR-TCD-5 KO CD19-directed CAR-TCD 5 KO CD19-directed CAR-T